Cargando…

Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus

INTRODUCTION: The objective of this study was to understand the potential use of single agents and drug combinations in multiple myeloma (MM) across treatment lines in the years 2021 and 2023. METHODS: The method used was Delphi Panel Method survey, administered to European Myeloma Network (EMN) Ita...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mario, Boccadoro, Patrizia, Berto, Sara, Bringhen, Elena, Zamagni, Patrizia, Tosi, Nicola, Cascavilla, Nicola, Giuliani, Donato, Mannina, Renato, Zambello, Francesca, Patriarca, Vittorio, Montefusco, Mariella, Grasso, Francesco, Di Raimondo, Massimo, Offidani, Teresa, Petrucci Maria, Pellegrino, Musto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AboutScience 2021
Materias:	Original Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9616197/ https://www.ncbi.nlm.nih.gov/pubmed/36627863 http://dx.doi.org/10.33393/grhta.2021.2245

Ejemplares similares

Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score
por: D’Agostino, Mattia, et al.
Publicado: (2021)

Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial
por: Saltarella, Ilaria, et al.
Publicado: (2019)

First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials
por: Larocca, Alessandra, et al.
Publicado: (2020)

Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs
por: Montefusco, Vittorio, et al.
Publicado: (2020)

Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies
por: Bringhen, Sara, et al.
Publicado: (2019)

Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study
por: Mina, Roberto, et al.
Publicado: (2020)

The Role of Monoclonal Antibodies in the First-Line Treatment of Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2020)

Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell’Adulto Multiple Myeloma Working Party study
por: Musto, Pellegrino, et al.
Publicado: (2015)

Experts’ consensus on the definition and management of high risk multiple myeloma
por: Marcon, Chiara, et al.
Publicado: (2023)

Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials
por: Gentile, Massimo, et al.
Publicado: (2020)

P1680: HEALTH-RELATED QUALITY OF LIFE IN TRANSPLANT-INELIGIBLE REAL-LIFE MULTIPLE MYELOMA PATIENTS TREATED WITH FIXED-DURATION BORTEZOMIB-MELPHALAN-PREDNISONE VS. CONTINUOUS LENALIDOMIDE-DEXAMETHASONE
por: D’agostino, Mattia, et al.
Publicado: (2023)

Ixazomib-based induction regimens plus ixazomib maintenance in transplant-ineligible, newly diagnosed multiple myeloma: the phase II, multi-arm, randomized UNITO-EMN10 trial
por: Mina, Roberto, et al.
Publicado: (2021)

Impact of minimal residual disease standardised assessment by FDG-PET/CT in transplant-eligible patients with newly diagnosed multiple myeloma enrolled in the imaging sub-study of the FORTE trial
por: Zamagni, Elena, et al.
Publicado: (2023)

P07 BORTEZOMIB-MELPHALAN-PREDNISONE (VMP) VS. LENALIDOMIDE-DEXAMETHASONE (RD) IN REAL-LIFE MULTIPLE MYELOMA PATIENTS INELIGIBLE FOR TRANSPLANT: UPDATED ANALYSIS OF THE RANDOMIZED PHASE IV REAL MM TRIAL
por: Larocca, A., et al.
Publicado: (2023)

Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies
por: Mina, Roberto, et al.
Publicado: (2020)

Lenalidomide-based induction and maintenance in elderly newly diagnosed multiple myeloma patients: updated results of the EMN01 randomized trial
por: Bringhen, Sara, et al.
Publicado: (2020)

Clinical features and survival of multiple myeloma patients harboring t(14;16) in the era of novel agents
por: Mina, Roberto, et al.
Publicado: (2020)

PB1984: ELOTUZUMAB PLUS LENALIDOMIDE AND DEXAMETHASONE IN RELAPSED/REFRACTORY MULTIPLE MYELOMA: EXTENDED 3-YEAR FOLLOW-UP OF AN ITALIAN, MULTICENTER, EXPERIENCE OUTSIDE OF CONTROLLED CLINICAL TRIALS
por: Bruzzese, A., et al.
Publicado: (2022)

IAO Systematic Review Award 2023
por: Jotz, Geraldo Pereira, et al.
Publicado: (2023)

P36 BELANTAMAB MAFODOTIN IN PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST ONE PROTEASOME INHIBITOR, ONE IMMUNOMODULATORY AGENT AND ONE ANTI-CD38 MONOCLONAL ANTIBODY: A RETRO-PROSPECTIVE ITALIAN OBSERVATIONAL STUDY
por: Offidani, M., et al.
Publicado: (2023)

Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf
por: Barilà, Gregorio, et al.
Publicado: (2021)

Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials
por: Morabito, Fortunato, et al.
Publicado: (2022)

A prospective observational study to assess clinical decision-making, prognosis, quality of life and satisfaction with care in patients with relapsed/refractory multiple myeloma: the CLARITY study protocol
por: Efficace, Fabio, et al.
Publicado: (2018)

Monoclonal Antibodies to Treat Multiple Myeloma: A Dream Come True
por: D’Agostino, Mattia, et al.
Publicado: (2020)

Emerging drugs and combinations to treat multiple myeloma
por: Larocca, Alessandra, et al.
Publicado: (2017)

Venetoclax-Rituximab Treatment of Relapsed/Refractory CLL During the COVID-19 Pandemic: A Real-Life Experience in Selected Central-Southern Italian Regions
por: Molica, Stefano, et al.
Publicado: (2021)

“Hemolysis, or not Hemolysis, that is the Question”. Use of Hydroxychloroquine in a Patient with COVID-19 Infection and G6PD Deficiency
por: Sgherza, Nicola, et al.
Publicado: (2020)

P804: PLASMA CELL LEUKEMIA-LIKE TRANSCRIPTOME OF BONE MARROW PLASMA CELLS AND CIRCULATING TUMOR CELL LEVELS IN PERIPHERAL BLOOD COMPLEMENTARILY DEFINE HIGH-RISK IN NEWLY DIAGNOSED MULTIPLE MYELOMA
por: D’agostino, Mattia, et al.
Publicado: (2023)

Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis
por: Oliva, Stefania, et al.
Publicado: (2016)

Safety of Rapid Daratumumab Infusion: A Retrospective, Multicenter, Real-Life Analysis on 134 Patients With Multiple Myeloma
por: Bonello, Francesca, et al.
Publicado: (2022)

The Role of Monoclonal Antibodies in Smoldering and Newly Diagnosed Transplant-Eligible Multiple Myeloma
por: Zamagni, Elena, et al.
Publicado: (2020)

Autologous transplant for myeloma: when the old meets the new
por: Gay, Francesca, et al.
Publicado: (2017)

Every‐other‐day palonosetron plus aprepitant for prevention of emesis following induction chemotherapy for acute myeloid leukemia: A randomized, controlled study from the “Rete Ematologica Pugliese”
por: Di Renzo, Nicola, et al.
Publicado: (2019)

P39 DEDALO: PHASE II STUDY OF DARATUMUMAB PLUS POMALIDOMIDE AND DEXAMETHASONE (DPD) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA AND 17P DELETION
por: Montefusco, V., et al.
Publicado: (2023)

Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor
por: Sgherza, Nicola, et al.
Publicado: (2021)

Tentative set-up of the DELPHI experiment
por: Kantardjian, G, et al.
Publicado: (1982)

Prospective evaluation of minimal residual disease in the phase II FORTE trial: a head-to-head comparison between multiparameter flow cytometry and next-generation sequencing
por: Oliva, Stefania, et al.
Publicado: (2023)

P20 LENALIDOMIDE MAINTENANCE AFTER VTD INDUCTION AND AUTOLOGOUS STEM CELL TRANSPLANTATION: PRELIMINARY RESULTS OF A REAL-LIFE STUDY INCLUDING 389 PATIENTS
por: Barilà, G., et al.
Publicado: (2023)

Quality of Response in Acute Myeloid Leukemia: The Role of Minimal Residual Disease
por: Maurillo, Luca, et al.
Publicado: (2019)

Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns
por: Cifola, Ingrid, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_7khij9ptrssgb2pvubpc4lv99p